StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for HROW yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $31.07 | $30.90 | -0.55% | 0.7M |
| 05-19 | $30.92 | $30.68 | -0.78% | 0.6M |
| 05-20 | $30.81 | $30.86 | +0.16% | 0.5M |
| 05-21 | $30.54 | $32.96 | +7.92% | 1.5M |
| 05-22 | $33.39 | $33.00 | -1.17% | 0.7M |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $44.20M | $272.30M | $183.21M | $111.57M |
Operating Income | $-22.08M | $30.52M | $14.92M | $177.00K |
Net Income | $-27.60M | $-5.14M | $-11.77M | $-12.79M |
EPS (Diluted) | $-0.74 | $-0.14 | $-0.32 | $-0.35 |
Total Assets | $419.54M | $399.48M | $363.07M | $345.03M |
Total Liabilities | $391.19M | $347.39M | $316.41M | $295.73M |
Cash & Equivalents | $94.64M | $72.93M | $74.29M | $52.96M |
Free Cash Flow OCF − CapEx | $-9.19M | $42.98M | $34.91M | $18.53M |
Shares Outstanding | 37.27M | 37.23M | 37.03M | 36.71M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.